BRIEF—Janssen wins label extension for Simponi

Janssen, the Johnson & Johnson subsidiary, has won a label extension on Simponi (golimumab).

The immunosuppressant, which is currently approved in the European Union for the treatment of several kinds of arthritis, receieved a further indication for ulcerative colitis.

Patients weighing less than 80kg, who have failed to respond to induction therapy, will now have the option to be treated with Simponi.